AJIM2401 - CME/CMLE - Immune checkpoint inhibitor–related colitis in patients on immunotherapy for cancer-Immune checkpoint inhibitor–related colitis in patients on immunotherapy for cancer

Immune checkpoint inhibitor–related colitis in patients on immunotherapy for cancer

Pdf Summary

The document "Immune checkpoint inhibitor–related colitis in patients on immunotherapy for cancer" discusses the prevalence, clinical presentation, histopathology, and underlying mechanisms of immune checkpoint inhibitor–related colitis in cancer patients undergoing immunotherapy. Belinda L. Sun and colleagues from the University of Arizona College of Medicine highlight that the condition is the most common immune-related adverse event associated with the use of immune checkpoint inhibitors and can lead to severe or life-threatening clinical issues.<br /><br />Key Points:<br />- Immune checkpoint inhibitor–related colitis is often severe and can lead to life-threatening issues in patients.<br />- Histopathological manifestations include acute and chronic active colitis, microscopic collagenous or lymphocytic colitis, and ischemic colitis.<br />- The proposed mechanisms behind immune checkpoint inhibitor–related colitis are linked to autoimmune-type dysregulation and alteration of the gut microbiome.<br /><br />Challenges and Future Research:<br />- Efforts are focused on predicting and managing immune-related adverse events more effectively.<br />- The goal is to understand the interplay between immune responses induced by immune checkpoint inhibitors to prevent adverse events while maintaining treatment efficacy.<br />- Research aims to identify biomarkers for colitis risk and innovative strategies for preventing and managing immune checkpoint inhibitor–related colitis.<br /><br />The document also delves into the role of the gut microbiome in immune-related colitis, emphasizing its association with treatment response and adverse events. Research shows a potential link between specific bacterial species and immune checkpoint inhibitor-related colitis, paving the way for personalized interventions based on gut microbiota composition.

Keywords

Immune checkpoint inhibitor–related colitis

Immunotherapy for cancer

Prevalence of colitis in cancer patients

Histopathology of immune-related colitis

Underlying mechanisms of immune checkpoint inhibitor–related colitis

Autoimmune-type dysregulation in colitis

Alteration of gut microbiome in colitis

Managing immune-related adverse events

Biomarkers for colitis risk

Role of gut microbiome in immune-related colitis